Drug Discovery

NXDC announces acquisition by German biotech firm

NX Development (NXDC), a privately-held life sciences company, has announced a merger acquisition under which NXDC became a wholly-owned subsidiary of photonamic GmbH & Co. KG (PHN).

PhoreMost, NeoPhore secure Innovate UK funding for small-molecule cancer immunotherapy program

PhoreMost and NeoPhore are set to receiv £1m of funding to develop a novel small-molecule cancer immunotherapy program following award of a Biomedical Catalyst grant in a recent Innovate UK competition.

Corvidia Therapeutics raises $60m funding to speed up clinical work

Corvidia Therapeutics has secured $60m in a Series B funding round to accelerate growth of its ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.

Scientists develop new method to make drugs smarter

Scientists from the University of Lincoln in the UK have created a new technique using nanotechnology which can make drugs more effective at reaching their target.

Tmunity raises another $35m to advance T Cell therapies

Tmunity Therapeutics, a biotherapeutics company focused on developing next-generation T cell immunotherapy, has raised new funding of $35m in a Series A investment from Kleiner Perkins and affiliates.

Shire rejects $63bn takeover proposal from Takeda

Ireland-based Shire has rejected a $63bn acquisition offer from Takeda Pharmaceutical, saying that it undervalues the company, its growth prospects and pipeline.

Sandoz, Pear to commercialize prescription digital therapeutics

Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients.

Novartis to invest $100m into antimalarials research

Novartis said that it will invest more than $100m to advance research and development of new antimalarials over the next five years.

Kalytera scraps pre-clinical programs in bone disease

Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs.